<DOC>
	<DOCNO>NCT00822315</DOCNO>
	<brief_summary>Raltegravir potent antiretroviral agent could use alternative efavirenz HIV-1 infect patient tuberculosis . However due pharmacokinetic interaction , optimal dose raltegravir use combination rifampin currently unknown . This phase II open-label randomize multicenter trial design estimate antiviral efficacy two dos raltegravir one dose efavirenz week 24 , HIV-1 naive patient co-infected active tuberculosis ( TB ) treat rifampin .</brief_summary>
	<brief_title>Efficacy Safety 2 Raltegravir Doses Naive HIV-1-infected Patients Receiving Rifampin Active Tuberculosis</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Adult patient ( least 18 year old ) Plasma HIV RNA &gt; 1000 copies/ml HIV1infection confirm ELISA Western blot Immunofluorescence ART na√Øve patient ART le 3 month 6 month ago ; HIV resistance genotype baseline show mutation NNRTI TDF 3TC require For woman childbearing age , negative urinary test pregnancy accept contraceptive method : condom use intrauterine device possible declare wish pregnancy come year . Confirmed probable TB TB treatment include rifampin start since 2 8 week randomisation Signed informed consent form For French patient , affiliate National Health Care System HIV2 infection ( single HIV1 ) Woman pregnant likely become , breastfeed refuse use contraception ALT &gt; 2.5N , Hb &lt; 7g/dl , neutrophil &lt; 750/mm3 , platelet &lt; 50 000/mm3 , bilirubin &gt; 5N , lipase &gt; 3N Creatinine clearance &lt; 60ml/min assessed Cockcroft method Ongoing psychiatric pathology condition ( include , limited , consumption alcohol drug ) might , investigator 's opinion , compromise safety treatment and/or patient compliance protocol Concomitant treatment include phenytoin phenobarbital ( compound interact UGT1A1 ) Prior TB Mycobacterium tuberculosis strain resistant rifampin TB treatment start 8 week randomisation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>HIV</keyword>
	<keyword>Tuberculosis</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Raltegravir</keyword>
	<keyword>France</keyword>
	<keyword>Brazil</keyword>
	<keyword>treatment naive</keyword>
</DOC>